Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HLCS | P50747 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | ABL1 | P00519 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.69 |
| ▸ | IDE | P14735 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 6/20 | 0.49 |
| ▸ | CA1 | P00915 | 6/20 | 0.49 |
| ▸ | CA2 | P00918 | 6/20 | 0.49 |
| ▸ | CA9 | Q16790 | 6/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6892316 | 1.00 | HLCS (1.00) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL16141170 | 1.00 | HLCS (1.00) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL14600958 | 1.00 | HLCS (1.00) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL12050323 | 1.00 | HLCS (1.00) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL16141168 | 0.98 | HLCS (0.97) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL11719002 | 0.94 | HLCS (0.88) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL29046885 | 0.85 | HLCS (0.73) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL7849030 | 0.85 | HLCS (0.73) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL19249123 | 0.84 | HLCS (1.00) | HLCSTDP1MEN1ABL1LMNA | |
| SCHEMBL22793211 | 0.84 | HLCS (0.73) | HLCSTDP1MEN1ABL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040170618-A1 | antagonists bind to a recognized target (e.g., a receptor); the enzyme component of the chimera then degrades the target resulting in a reduction of activity of the target and release of the chimeric molecule, which is then free to attack and degrade another target molecule. | DAVIS BENJAMIN G (GB) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040170618-A1 | antagonists bind to a recognized target (e.g., a receptor); the enzyme component of the chimera then degrades the target resulting in a reduction of activity of the target and release of the chimeric molecule, which is then free to attack and degrade another target molecule. | ENGASE, GPR84, ADGRF1 | HLCS 2073/4885TDP1 3376/4885MEN1 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.